Dianthus Therapeutics, Inc. /DE/ Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 181.73 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 70.00K shares, a 58.01% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 111.73K shares, a 36.81% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 55.43K shares, a 41.71% decline year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 37.47K shares, a 476.40% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 314.01K shares, a 70.24% increase from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 184.45K shares, a 72.12% decline from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 661.60K shares.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 2.05M shares, a 51.94% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 70.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 181.73K shares 10-Q · filed 2026-08-04 | 237.16K shares derived: sum of 3 quarters · filed 2026-08-04 | 274.63K shares derived: sum of 4 quarters · filed 2026-08-04 | |
| 2026-03-31 | 111.73K shares 10-Q · filed 2026-05-05 | 167.16K shares derived: sum of 2 quarters · filed 2026-05-05 | 204.63K shares derived: sum of 3 quarters · filed 2026-05-05 | 248.93K shares derived: sum of 4 quarters · filed 2026-05-05 | |
| 2025-12-31 | 55.43K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | 92.90K shares derived: sum of 2 quarters · filed 2026-03-09 | 137.20K shares derived: sum of 3 quarters · filed 2026-03-09 | 314.01K shares 10-K · filed 2026-03-09 | |
| 2025-09-30 | 37.47K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 81.77K shares derived: sum of 2 quarters · filed 2025-11-05 | 258.58K shares 10-Q · filed 2025-11-05 | 353.68K shares derived: sum of 4 quarters · filed 2025-11-05 | |
| 2025-06-30 | 44.30K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 221.12K shares 10-Q · filed 2025-08-07 | 316.21K shares derived: sum of 3 quarters · filed 2025-08-07 | 322.71K shares derived: sum of 4 quarters · filed 2025-08-07 | |
| 2025-03-31 | 176.81K shares 10-Q · filed 2025-05-12 | 271.91K shares derived: sum of 2 quarters · filed 2025-05-12 | 278.41K shares derived: sum of 3 quarters · filed 2025-05-12 | 339.46K shares derived: sum of 4 quarters · filed 2025-05-12 | |
| 2024-12-31 | 95.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 101.60K shares derived: sum of 2 quarters · filed 2025-03-11 | 162.65K shares derived: sum of 3 quarters · filed 2025-03-11 | 184.45K shares 10-K · filed 2025-03-11 | |
| 2024-09-30 | 6.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 67.55K shares derived: sum of 2 quarters · filed 2024-11-07 | 89.36K shares 10-Q · filed 2024-11-07 | 282.66K shares derived: sum of 4 quarters · filed 2024-11-07 | |
| 2024-06-30 | 61.05K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 82.86K shares 10-Q · filed 2024-08-08 | 276.16K shares derived: sum of 3 quarters · filed 2024-08-08 | ||
| 2024-03-31 | 21.81K shares 10-Q · filed 2024-05-09 | 215.11K shares derived: sum of 2 quarters · filed 2024-05-09 | |||
| 2023-12-31 | 193.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 661.60K shares 10-K · filed 2024-03-21 | |||
| 2023-09-30 | 468.29K shares 10-Q · filed 2023-11-09 | ||||
| 2022-12-31 | 6.72K shares 8-K · filed 2023-12-21 | 2.28M shares 10-K · filed 2023-03-23 | |||
| 2021-12-31 | 2.05M shares 10-K · filed 2022-03-08 | ||||
| 2020-12-31 | 1.35M shares 10-K · filed 2021-03-03 | ||||
| 2019-12-31 | 336.95K shares 10-K · filed 2020-03-03 | ||||
| 2018-12-31 | 233.45K shares 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |